Impedimed's share price is up by 55% since its stunning announcement on Monday morning

Impedimed's share price is up by 55% since its stunning announcement on Monday morning. This was regarding the 'Centers for Medicare and Medicaid Services' assigning a reimbursement rate of US$112.67 for Impedimed's test. This compares to company guidance of US$30 - US$50. Matthijs Smith previously used US$30 in his models. This change has obviously resulted in a step change in his valuation, which increased by a remarkable 164% from $0.70 to $1.85. This may yet leave further upside, as his model assumes that the company only receives US$85 per test. More upside may also come from testing protocols that stipulate more frequent testing. Many clinics are testing their patients 17 times over a four-year period, and more frequently if they do develop lymphoedema. This compares to our model, which assumes eight tests per patient in this time frame. Impedimed has already gained 211% since Matthijs initiated on 12th march at $0.225, and the stock now trades at his previous valuation of $0.70. With the new upgrade in price target to $1.85, the stock firmly remains a buy. Research here: (VIEW LINK)